3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Bevacizumab
9
Oxaliplatin
7
Irinotecan
6
Fluorouracil
6
Nivolumab
5
Leucovorin
5
Cetuximab
5
Capecitabine
5
pembrolizumab
4
Sunitinib
4
IFL protocol
4
Drug Therapy
4
Cisplatin
4
encorafenib
3
Pemetrexed
3
Gemcitabine
3
Folfox protocol
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
trastuzumab deruxtecan
2
amminedichloro(2-methylpyridine)platinum(II)
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Levoleucovorin
2
IDRX-42
2
CGX1321
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
ulixertinib
1
tivozanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastrointestinal Neoplasms
×
MAA868
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled